Predicting ACI Outcomes with GMP In-Process Control Kinetic Metrics: Initial Chondrocyte Yield and Population Doubling Time as Prognostic Clinical Biomarkers.

Virginie Philippe, Alexis E Laurent, André Berchtold, Nathalie Hirt-Burri, Lee Ann Applegate, Robin Martin

Abstract read

In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Virginie PhilippeOrthopedics and Traumatology Service, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.ORCID 0000-0003-3544-0383

Alexis E LaurentManufacturing Department, LAM Biotechnologies SA, CH-1066 Epalinges, Switzerland.ORCID 0000-0001-5738-8702

André BerchtoldInstitute of Social Sciences, University of Lausanne, CH-1015 Lausanne, Switzerland.ORCID 0000-0002-0711-2254

Nathalie Hirt-BurriRegenerative Therapy Unit, Plastic, Reconstructive and Hand Surgery Service, Lausanne University Hospital, University of Lausanne, CH-1066 Epalinges, Switzerland.

Lee Ann ApplegateRegenerative Therapy Unit, Plastic, Reconstructive and Hand Surgery Service, Lausanne University Hospital, University of Lausanne, CH-1066 Epalinges, Switzerland.

Robin MartinOrthopedic Surgery Service, Fribourg Hospital, CH-1752 Villars-sur-Glâne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine whether specific in vitro biologic characteristics and manufacturing kinetics of cultured human articular chondrocytes (HACs) can serve as predictive biomarkers for patient-reported and structural outcomes following second-generation autologous chondrocyte implantation (ACI) in the knee. MATERIALS AND

methodsThis prospective cohort study evaluated 67 patients (mean age 25.1 ± 8.3 years) treated with second-generation ACI for large focal cartilage defects (mean size 5.4 ± 2.5 cm

resultsStatic biosynthetic markers (

conclusionsThe intrinsic proliferative vigor of the HAC cellular payload (shorter PDT) and higher initial cell yields are robust kinetic biomarkers associated with markedly superior mid-term clinical outcomes following second-generation ACI for large focal chondral defects in the knee. In contrast, standard morphological and gene expression metrics failed to predict in vivo functional success. These findings advocate for a risk-based paradigm shift in GMP quality control methodologies, emphasizing dynamic HAC growth kinetics over static cellular features to optimize patient-specific regenerative potential.

Indexed as

autologous chondrocyte implantationcartilage repaircell therapycryopreservationGood Manufacturing Practiceshuman articular chondrocyteskneepatient-reported outcome measurespopulation doubling timeprognostic indicators

Identifiers

PMID42652985

DOI10.3390/life16081297

PMCPMC13514264

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.